Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Blue Owl Capital Holdings LP

Q2 2024 · 13F-HR

Blue Owl Capital Holdings LPholdings as filed

Filed 2024-08-15 · accession 0000950123-24-008845

$359.6M
Reported value
41
Positions
2024-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
230031106CGEMCULLINAN THERAPEUTICS INC$35.7M9.94%2,049,172CommonSOLE
729139105PLRXPLIANT THERAPEUTICS INC$32.3M8.98%3,004,199CommonSOLE
69121K104OBDCBLUE OWL CAPITAL CORPORATION$31.4M8.74%2,045,070CommonSOLE
49845K101KVYOKLAVIYO INC$29.8M8.29%1,198,270CommonSOLE
517125100LRMRLARIMAR THERAPEUTICS INC$28.0M7.78%3,859,468CommonSOLE
29286M105ENGENE HOLDINGS INC$23.1M6.43%2,449,827CommonSOLE
89157D105TRMLTOURMALINE BIO INC$22.1M6.14%1,715,401CommonSOLE
29977X105EVCMEVERCOMMERCE INC$18.0M5.01%1,641,929CommonSOLE
00445A100ACELYRIN INC$12.9M3.59%2,926,028CommonSOLE
760273102RPTXREPARE THERAPEUTICS INC$11.1M3.10%3,372,499CommonSOLE
90400D108RAREULTRAGENYX PHARMACEUTICAL IN$11.0M3.07%268,238CommonSOLE
21077P108CNTXCONTEXT THERAPEUTICS INC$10.3M2.88%5,161,290CommonSOLE
254604101IRONDISC MEDICINE INC$9.7M2.70%215,260CommonSOLE
888787108TOSTTOAST INC$8.3M2.31%322,578CommonSOLE
29788T103ETWOGBPE2OPEN PARENT HOLDINGS INC$7.4M2.06%1,650,943CommonSOLE
492327101KROSKEROS THERAPEUTICS INC$7.2M2.00%157,633CommonSOLE
45175G108IKENA ONCOLOGY INC$6.8M1.88%4,091,118CommonSOLE
786700104SGMTSAGIMET BIOSCIENCES INC$5.7M1.59%1,673,877CommonSOLE
603170101MLYSMINERALYS THERAPEUTICS INC$5.3M1.47%450,339CommonSOLE
92686J106VKTXVIKING THERAPEUTICS INC$5.0M1.40%95,000CommonSOLE
45790W108INOZYME PHARMA INC$5.0M1.39%1,120,027CommonSOLE
85571B105STWDSTARWOOD PROPERTY TRUST$4.3M1.19%226,456CommonSOLE
747324101PYXSPYXIS ONCOLOGY INC$3.5M0.96%1,046,025CommonSOLE
589492107MREOMEREO BIOPHARMA GROUP PLC$3.2M0.90%897,809CommonSOLE
03843E104AQSTAQUESTIVE THERAPEUTICS INC$3.0M0.82%1,140,000CommonSOLE
20454B104CMPXCOMPASS THERAPEUTICS INC$2.8M0.79%2,829,712CommonSOLE
H0036K147ADCTADC THERAPEUTICS SA$2.3M0.64%733,568CommonSOLE
68217N105OMEGA THERAPEUTICS INC$2.2M0.61%1,055,882CommonSOLE
86366E106GPCRSTRUCTURE THERAPEUTICS INC$2.2M0.60%55,000CommonSOLE
45258J102IMVTIMMUNOVANT INC$2.1M0.59%80,000CommonSOLE
87184Q206SYRSSYROS PHARMACEUTICALS INC$1.8M0.49%340,855CommonSOLE
47103J105JANXJANUX THERAPEUTICS INC$1.7M0.47%40,000CommonSOLE
15102K100CELCCELCUITY INC$1.1M0.30%65,000CommonSOLE
09352U108BLNDBLEND LABS INC$853,3510.24%361,587CommonSOLE
38046W204GOCOGOHEALTH INC$814,6310.23%83,264CommonSOLE
29286M113ENGENE HOLDINGS INC$608,3010.17%51,177CommonSOLE
G63290129PLMUFPLUM ACQUISITION CORP III$324,0010.09%70,000CommonSOLE
25058X303DM*DESKTOP METAL INC$309,7500.09%750,000CommonSOLE
74019P207DTILPRECISION BIOSCIENCES INC$196,7410.05%20,220CommonSOLE
374163103GERNGERON CORPORATION$101,4120.03%23,918CommonSOLE
G63290103PLMWFPLUM ACQUISITION CORP III$46,6670.01%666,666CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.